Cosciens Biopharma(OTC) CSCIF

Market Cap$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-97%
1 Year-18%
1 Month+29%
$6.44
+0.31%
+0.02Today
Cosciens Biopharma last closing stock price
MetricPriceDate
Last closeUSD 6.442026-10-02
Cosciens Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.57%USD 6.102026-09-25
1 month+29.32%USD 4.982026-09-01
3 month-12.38%USD 7.352026-07-02
Year to date+4.21%USD 6.182025-12-31
1 year-17.75%USD 7.832025-10-02
3 year-75.83%USD 26.642023-10-03
5 year-97.21%USD 231.002021-10-01
Since inception-100%USD 1,912,484.702000-05-10

Cosciens Biopharma Financials at a Glance

Market Cap

$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.27M

Net Income (TTM)

-$4.76M

EPS (TTM)

-$4.48

P/E Ratio

-1.44

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.44

Volume

1

Open

$6.44

Previous Close

$6.44

Daily Range

$6.44 - $6.44

52-Week Range

$2.37 - $9.57

Estimated Earnings Date

Nov 10, 2026

CSCIF News

Tackling Cancer: Your Best Investing Ideas

Sean WilliamsJun 1, 2013
Endometrial cancer

Tackling Cancer: Endometrial Cancer's Biggest Current and Upcoming Players

Sean WilliamsMay 11, 2013

Aeterna Zentaris Names New CEO

Eric VolkmanApr 15, 2013

This Week in Biotech

Sean WilliamsMar 16, 2013

Breakdown of This Biotech Massacre

Dave WilliamsonMar 11, 2013

Will the Feuerstein-Ratain Rule Hold in 2013?

Maxx ChatskoJan 18, 2013
oprhan drugs

Do Orphan Drug Developers Belong in Your Portfolio?

Sean WilliamsJan 15, 2013

This Week in Biotech

Sean WilliamsJan 5, 2013
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosciens Biopharma

COSCIENS Biopharma Inc. is a life science company focused on developing and commercializing products for the cosmeceutical, nutraceutical, and pharmaceutical markets. The company operates through its Active Ingredient and Pharmaceutical segments, offering innovative solutions to enhance health and wellness.

Products and Services
  • Active ingredients like oat beta glucan for health support
  • Macrilen/Ghryvelin, a growth hormone secretagogue
  • Oat oil and peptides for cosmeceutical applications
Growth Outlook
  • Revenue increased to $3.14 million in Q2 2026, up from $1.86 million in Q1 2026
  • Gross profit margin improved to 55.3% in Q2 2026
  • Strong cash position with $5.27 million in cash as of June 2026
Financial Highlights
  • Trailing twelve months (TTM) revenue of $10.5 million
  • Operating income of $421,179 in Q2 2026, indicating operational efficiency
  • Current ratio of 4.33, reflecting strong liquidity
COSCIENS Biopharma Inc. has shown promising growth in recent quarters, particularly with a significant increase in revenue and an improved gross profit margin. The company's focus on innovative health solutions positions it well within the competitive landscape of the pharmaceutical industry. With a solid cash position and a favorable current ratio, COSCIENS is equipped to navigate future challenges and capitalize on growth opportunities. The diverse product offerings, including active ingredients and pharmaceuticals, cater to a wide range of market needs, enhancing the company's potential for sustained success.
AI Generated • Sep 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Peter Harry Puccetti, CFA

Website

www.cosciensbio.com

Headquarters

Toronto, ON M5H 4E3, CA

CSCIF Financials

Key Financial Metrics (TTM)

Gross Margin

45.30%

Operating Margin

-58.56%

Net Income Margin

-57.93%

Return on Equity

-48.52%

Return on Capital

-177.65%

Return on Assets

-25.17%

Earnings Yield

-69.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

996.40K

Volume

1

Avg. Volume

714.245

Financials (TTM)

Gross Profit

$3.75M

Operating Income

-$5.04M

EBITDA

-$3.24M

Operating Cash Flow

-$3.94M

Capital Expenditure

-$43.20K

Free Cash Flow

-$3.99M

Cash & ST Invst.

$5.27M

Total Debt

$1.95M

Cosciens Biopharma Performance Analysis

Cosciens Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,640,0007.2%
20232023-12-31USD 7,143,00026.6%
20242024-12-31USD 9,587,00034.2%
20252025-12-31USD 7,498,000-21.8%
Cosciens Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-46.1%
Q42025-12-3120.8%
Q12026-03-313.9%
Q22026-06-3068.5%
Cosciens Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -56.16157.1%
20232023-12-31USD -22.64-59.7%
20242024-12-31USD -17.79-21.4%
20252025-12-31USD -9.82-44.8%
Cosciens Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3032.9%
Q42025-12-31-22.8%
Q12026-03-3175.7%
Q22026-06-3087.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.14M

+14.1%

Gross Profit

$1.73M

+78.0%

Gross Margin

55.27%

N/A

Market Cap

$6.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$229.17K

N/A

Employees

28

N/A

Net Income

-$201.61K

+92.5%

EBITDA

$757.53K

+131.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.27M

-43.6%

Total Debt

$1.95M

-13.5%

Accounts Receivable

$2.37M

-15.0%

Inventory

$958.14K

-47.4%

Long Term Debt

$1.77M

-13.8%

Short Term Debt

$186.64K

-10.7%

Return on Assets

-25.17%

N/A

Return on Invested Capital

-28.87%

N/A

Free Cash Flow

$563.74K

+112.5%

Operating Cash Flow

$571.51K

+112.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KPRXKiora Pharmaceuticals, Inc.
$2.54-0.78%
DCOYDecoy Therapeutics Inc.
$1.69-4.52%
AFMDQAffimed N.V.
$0.00+100.00%
IMUCEOM Pharmaceuticals Holdings, Inc.
$0.12-24.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
EWZiShares - iShares Msci Brazil ETF
$43.25+13.25%
NUNu Holdings
$15.16+12.88%
ITUBItaú Unibanco
$9.97+16.01%
SPCXSpace Exploration Technologies
$168.38+5.93%

Questions About CSCIF

What is the current price of Cosciens Biopharma?

Cosciens Biopharma is trading at $6.44 per share.

What is the 52-week range for Cosciens Biopharma?

Over the past 52 weeks, Cosciens Biopharma has traded between $2.37 and $9.57.

How much debt does Cosciens Biopharma have?

As of the most recent reporting period, Cosciens Biopharma reported total debt of $1.96M.

How much cash does Cosciens Biopharma have on hand?

Cosciens Biopharma reported $5.28M in cash and cash equivalents in its most recent financial results.

What is Cosciens Biopharma’s dividend yield?

Cosciens Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services